Jiangxi Fushine Pharmaceutical Co., Ltd.'s wholly-owned subsidiary, Jiangxi Xiangtai Life Sciences Co., Ltd. (hereinafter referred to as "Xiangtai Sciences"), recently received the "Notice of Drug GMP Compliance Inspection Results of the Jiangxi Provincial Drug Administration" (No. 16 of 2024) issued by the Jiangxi Provincial Drug Administration.

Paroxetine acid

The product that passed the GMP compliance inspection at Xiangtai Scientific this time is the API (paroxetine hydrochloride, WO6 workshop, paroxetine hydrochloride production line). Paroxetine hydrochloride is primarily used to treat adult depression. Currently, most paroxetine available in China is an oral sustained-release preparation and is a commonly used antidepressant. According to data from MinEnet, total sales of paroxetine in the domestic medical market reached RMB 586 million in 2021.
Depression has high morbidity, high recurrence, and high disability rates, yet overall diagnosis and treatment rates are low. According to the World Health Organization, depression has become the fourth most common illness in the world, with over 350 million people suffering from depressive illnesses worldwide. According to the "2022 National Depression Blue Book," the number of people suffering from depression in my country is approximately 95 million, a significant number. As more and more patients seek treatment, the market potential is vast.
The passing of the pharmaceutical GMP compliance inspection indicates that Xiangtai Scientific's related products and production lines meet GMP requirements, which will be conducive to promoting the domestic production and market launch of Xiangtai Scientific's paroxetine hydrochloride raw material products, and is expected to improve Xiangtai Scientific's performance and promote the sustainable and healthy development of Xiangtai Scientific.
Xiangtai Science will arrange production and sales according to market demand and continue to maintain a good production management and quality assurance system.

Shota Science

Xiangtai Scientific, a wholly-owned subsidiary of Fushine Pharmaceuticals, occupies approximately 300 mu (approximately 1,000 acres) of land. Its existing facilities and equipment enable it to achieve an annual output value of 1.5 billion yuan. Xiangtai Scientific is a modern pharmaceutical enterprise with first-class technology, equipment, and management. Dedicated to the production of anti-infective and sterile drugs, it provides high-quality, one-stop CDMO services for the development and production of new drugs worldwide. Its freeze-drying sterile workshops and sterility assurance levels are among the best in the industry nationwide.